Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 11 studies | 33% ± 19% | |
| astrocyte | 7 studies | 39% ± 16% | |
| GABAergic neuron | 3 studies | 35% ± 8% | |
| glutamatergic neuron | 3 studies | 49% ± 2% | |
| ependymal cell | 3 studies | 59% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 5 studies | 28% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 450.65 | 2640 / 2642 | 81% | 1.69 | 570 / 705 |
| thymus | 100% | 347.85 | 653 / 653 | 56% | 1.04 | 337 / 605 |
| kidney | 100% | 225.99 | 89 / 89 | 42% | 0.74 | 379 / 901 |
| adrenal gland | 97% | 172.53 | 250 / 258 | 42% | 0.59 | 96 / 230 |
| breast | 92% | 98.04 | 420 / 459 | 38% | 0.61 | 421 / 1118 |
| ovary | 92% | 96.03 | 165 / 180 | 34% | 0.55 | 148 / 430 |
| prostate | 97% | 117.85 | 237 / 245 | 18% | 0.23 | 90 / 502 |
| uterus | 95% | 107.12 | 162 / 170 | 12% | 0.21 | 55 / 459 |
| lung | 91% | 152.18 | 527 / 578 | 14% | 0.26 | 159 / 1155 |
| bladder | 95% | 116.00 | 20 / 21 | 5% | 0.11 | 26 / 504 |
| esophagus | 84% | 120.88 | 1208 / 1445 | 14% | 0.21 | 26 / 183 |
| pancreas | 79% | 65.47 | 258 / 328 | 15% | 0.21 | 26 / 178 |
| stomach | 76% | 76.34 | 272 / 359 | 17% | 0.26 | 48 / 286 |
| intestine | 83% | 106.54 | 798 / 966 | 10% | 0.13 | 51 / 527 |
| blood vessel | 81% | 76.54 | 1082 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 75% | 62.40 | 907 / 1204 | 0% | 0 | 0 / 0 |
| skin | 54% | 51.82 | 975 / 1809 | 3% | 0.04 | 15 / 472 |
| heart | 53% | 40.62 | 459 / 861 | 0% | 0 | 0 / 0 |
| muscle | 5% | 3.21 | 41 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 4% | 0.06 | 2 / 45 |
| liver | 2% | 1.01 | 4 / 226 | 2% | 0.03 | 8 / 406 |
| spleen | 3% | 1.78 | 7 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 1% | 0.40 | 6 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002357 | Biological process | defense response to tumor cell |
| GO_0043280 | Biological process | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process |
| GO_0043409 | Biological process | negative regulation of MAPK cascade |
| GO_0005575 | Cellular component | cellular_component |
| GO_0003674 | Molecular function | molecular_function |
| Gene name | CASC2 |
| Protein name | Protein CASC2, isoforms 1/2 (Cancer susceptibility candidate gene 2 protein isoforms 1/2) Protein CASC2, isoform 3 (Cancer susceptibility candidate gene 2 protein, isoform 3) |
| Synonyms | C10orf5 |
| Description | FUNCTION: May act as a potential tumor suppressor. . |
| Accessions | Q6XLA1 Q8IU53 |